Open Journal Systems

The future perspective of PARP inhibitors

Kwong-Kwok Wong ()

Abstract


The protein poly (ADP-ribose) polymerase (PARP) plays an important role in DNA base excision repair and repair of DNA single-strand breaks[1] and might also be involved in DNA double-strand break repair[2]. For tumor cells with homologous recombination deficiency (HRD), such as ovarian cancer cells with BRCA1/2 mutations, interfering with PARP activity leads to unrepaired single-strand DNA breaks and subsequent formation of double- strand breaks. This results in synthetic lethality of cancer cells with HRD. In 2005, the antitumor effect of inhibiting the PARP enzyme in BRCA1/2-mutated cancer cells was first demonstrated in preclinical tumor xenografts[3,4]. After a decade of developing drugs targeting PARP for clinical use in patients with BRCA- mutated cancer, in recent years several PARP inhibitors have finally been approved by the U.S. Food and Drug Administration for the treatment of ovarian cancer.

Keywords


PARP inhibitor; targeted therapy; immunotherapy; ovarian cancer

Full Text:

PDF

References


Caldecott KW. DNA single-strand break repair. Exp Cell Res 2014; 329(1): 2–8. doi: 10.1016/j. yexcr.2014.08.027.

Frit P, Barboule N, Yuan Y, Gomez D, Calsou P. Alternative end-joining pathway(s): Bricolage at DNA breaks. DNA Repair (Amst) 2014; 17: 81–97. doi: 10.1016/j. 2014.02.007.

Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434(7035): 917–921. doi: 10.1038/nature03445.

Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005; 434(7035): 913–917. doi: 10.1038/nature 03443.

US Food and Drug Administration. FDA approves olaparib tablets for maintenance treatment in ovarian cancer. Accessed August 2017.

Balasubramaniam S, Beaver JA, Horton S, Fernandes LL, Tang S, et al. FDA approval summary: Rucaparib for the treatment of patients with deleterious BRCA mutation-associated advanced ovarian cancer. Clin Cancer Res 2017; 23(23): 7165–7170. doi: 10.1158/1078-0432. CCR-17-1337.

Mechcatie E. FDA approves PARP inhibitor for ovarian cancer. Nat Biotechnol 2017; 35(5): 398. doi: 10.1038/nbt 0517-398.

Yang L, Zhang Y, Shan W, Hu Z, Yuan J, et al. Repression of BET activity sensitizes homologous recombination-proficient cancers to PARP inhibition. Sci Transl Med 2017; 9(400). doi: 10.1126/ scitrans-lmed.aal1645.

Du Y, Yamaguchi H, Wei Y, Hsu JL, Wang HL, et al. Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors. Nat Med 2016; 22(2): 194–201. doi: 10.1038/nm. 4032.

Sun C, Fang Y, Yin J, Chen J, Ju Z, et al. Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers. Sci Transl Med 2017; 9(392). doi: 10.1126/ scitranslmed.aal5148.

Zanjirband M, Curtin N, Edmondson RJ, Lunec J. Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer. Oncotarget 2017; 8(41): 69779- 69796. doi: 10.18632/oncotaret.19266.

Wang D, Li C, Zhang Y, Wang M, Jiang N, et al. Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes. Gynecol Oncol 2016; 142(3): 548–556. doi: 10.1016/j.ygyno. 2016.07.092.

Allegrezza MJ, Rutkowski MR, Stephen TL, Svoronos N, Tesone AJ, et al. IL15 agonists overcome the immunosuppressive effects of Mek inhibitors. Cancer Res 2016; 76(9): 2561–2572. doi: 10.1158/0008-5472.CAN- 15-2808.

Allegrezza MJ, Conejo-Garcia JR. Targeted therapy and immunosuppression in the tumor microenvironment. Trends Cancer 2017; 3(1): 19–27. doi: 10.1016/j.trecan. 2016.11.009.

Ovarian Tumor Tissue Analysis Consortium, Goode EL, Block MS, Kalli KR, Vierkant RA, et al. Dose-response association of CD8+tumor-infiltrating lymphocytes and survival time in high-grade serous ovarian cancer. JAMA Oncol 2017: e173290. doi: 10.1001/jamaoncol.2017.3290.

Higuchi T, Flies DB, Marjon NA, Mantia-Smaldone G, Ronner L, et al. CTLA-4 blockade synergizes therapeutically with PARP inhibition in BRCA1-deficient ovarian cancer. Cancer Immunol Res 2015; 3(11): 1257–1268. doi: 10.1158/2326-6066.CIR-15-0044.

Evans KW, Yuca E, Akcakanat A, Scott SM, Arango NP, et al. A population of heterogeneous breast cancer patient-derived xenografts demonstrate broad activity of PARP inhibitor in BRCA1/2 wild-type tumors. Clin Cancer Res 2017; 23(21): 6468–6477. doi: 10.1158/1078-0432.CCR-17-0615.

Li L, Karanika S, Yang G, Wang J, Park S, et al. Androgen receptor inhibitor-induced “BRCAness” and PARP inhibition are synthetically lethal for castration-resistant prostate cancer. Sci Signal 2017; 10(480). doi:10.1126/ scisignal.aam7479.



DOI: http://dx.doi.org/10.30564/amor.v3i6.140

Refbacks

  • There are currently no refbacks.


Copyright (c) 2018 Kwong-Kwok Wong

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.